INDBInternet News Database 2.5 Updated 2 min ago · 306 sources Show or hide images Light or dark

Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial

Save Like Comments Compare coverage
Image from Quartz

Summary

Company plans to meet with the FDA and is preparing a biologics license application for the first half of 2027

Description from Quartz.

Who is covering this

  1. Quartz Leans left Factuality: High US
    Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial

    Company plans to meet with the FDA and is preparing a biologics license application for the first half of 2027

Comments

Comments need JavaScript.